All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Lilly USA, LLC, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
Results from the long-term follow-up of the randomized, phase III GLOW (NCT03462719) trial, evaluating fixed-duration ibrutinib + venetoclax vs chlorambucil + obinutuzumab in older and/or comorbid patients with previously untreated chronic lymphocytic leukemia (CLL), were published in Leukemia by Niemann et al. Endpoints of the long-term analysis include overall survival (OS), time to next treatment (TTNT), and progression-free survival in the intent-to-treat (ITT) population.
Key data: Patients in the ITT analysis were randomized to receive ibrutinib + venetoclax (n = 106) or chlorambucil + obinutuzumab (n = 105). At 67-month median follow-up, ibrutinib + venetoclax reduced the risk of death by 54% vs chlorambucil + obinutuzumab (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.27–0.78; p = 0.003). The 66-month OS rates were 79.0% (95% CI, 69.5–85.8) with ibrutinib + venetoclax vs 60.8% (95% CI, 50.7–69.6) with chlorambucil + obinutuzumab. Ibrutinib + venetoclax significantly improved PFS (66-month rates: 51.7% vs 18.1%; HR, 0.27; p < 0.001) and reduced the risk of requiring second-line therapy by 77% (HR, 0.23; 95% CI, 0.13–0.40; p < 0.001). Grade 3/4 treatment-emergent adverse event (TEAE)-free PFS was 51.6 months with ibrutinib + venetoclax vs 30.2 months with chlorambucil + obinutuzumab (p = 0.005).
Key learning: At 67 months of follow-up, fixed-duration ibrutinib + venetoclax demonstrated durable disease control and superior OS and PFS vs chlorambucil + obinutuzumab in older and/or comorbid patients with CLL, with meaningful gains in toxicity-free survival. These results support ibrutinib + venetoclax as a first-line therapy in this population.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
In which lymphoma subtypes do you currently use next-generation sequencing as part of the diagnostic work-up in your practice?